Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jong-Mu Sun

Showing results (181-190 of 303) with videos related to

Pageof 31
Sort By:
Lung Cancer (Amsterdam, Netherlands)|May 15, 2012
Chemotherapy for pulmonary large cell neuroendocrine carcinoma: similar to that for small cell lung cancer or non-small cell lung cancer?Jong-Mu Sun, Myung-Ju Ahn, Jin Seok Ahn, et al.
Oncotarget|September 15, 2017
Correction: A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01)Hye Ryun Kim, Joung Soon Jang, Jong-Mu Sun, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 23, 2015
The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase InhibitorsJi Yun Lee, Bo Mi Ku, Sung Hee Lim, et al.
Oncotarget|November 9, 2016
A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01)Hye Ryun Kim, Joung Soon Jang, Jong-Mu Sun, et al.
The Lancet. Oncology|September 19, 2014
Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient dataAntonio Rossi, Paolo Chiodini, Jong-Mu Sun, et al.
Oncoimmunology|February 21, 2020
Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatmentKyung Hwan Kim, Joon Young Hur, Jinhyun Cho, et al.
Cancer Medicine|June 23, 2018
Surgically resected T1- and T2-stage esophageal squamous cell carcinoma: T and N staging performance of EUS and PET/CTDong Young Jeong, Min Yeong Kim, Kyung Soo Lee, et al.
Future Oncology (London, England)|October 29, 2024
TROPION-Lung07: Phase III study of Dato-DXd + pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancerIsamu Okamoto, Shoichi Kuyama, Nicolas Girard, et al.
Immune Network|January 11, 2021
Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 AbsKyung Hwan Kim, Joon Young Hur, Jiae Koh, et al.
Radiation Oncology (London, England)|December 15, 2018
Clinical outcomes of radiation therapy for clinical T4b oesophageal cancer with airway invasionHakyoung Kim, Dongryul Oh, Yong Chan Ahn, et al.
Pageof 31

Showing results (181-190 of 303) with videos related to

Sort By:
Pageof 31
Lung Cancer (Amsterdam, Netherlands)|May 15, 2012
Chemotherapy for pulmonary large cell neuroendocrine carcinoma: similar to that for small cell lung cancer or non-small cell lung cancer?Jong-Mu Sun, Myung-Ju Ahn, Jin Seok Ahn, et al.
Oncotarget|September 15, 2017
Correction: A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01)Hye Ryun Kim, Joung Soon Jang, Jong-Mu Sun, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 23, 2015
The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase InhibitorsJi Yun Lee, Bo Mi Ku, Sung Hee Lim, et al.
Oncotarget|November 9, 2016
A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01)Hye Ryun Kim, Joung Soon Jang, Jong-Mu Sun, et al.
The Lancet. Oncology|September 19, 2014
Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient dataAntonio Rossi, Paolo Chiodini, Jong-Mu Sun, et al.
Oncoimmunology|February 21, 2020
Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatmentKyung Hwan Kim, Joon Young Hur, Jinhyun Cho, et al.
Cancer Medicine|June 23, 2018
Surgically resected T1- and T2-stage esophageal squamous cell carcinoma: T and N staging performance of EUS and PET/CTDong Young Jeong, Min Yeong Kim, Kyung Soo Lee, et al.
Future Oncology (London, England)|October 29, 2024
TROPION-Lung07: Phase III study of Dato-DXd + pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancerIsamu Okamoto, Shoichi Kuyama, Nicolas Girard, et al.
Immune Network|January 11, 2021
Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 AbsKyung Hwan Kim, Joon Young Hur, Jiae Koh, et al.
Radiation Oncology (London, England)|December 15, 2018
Clinical outcomes of radiation therapy for clinical T4b oesophageal cancer with airway invasionHakyoung Kim, Dongryul Oh, Yong Chan Ahn, et al.
Pageof 31